HUP0301214A2 - Tisztítási eljárás csökkentett dimer szennyező tartalmú lovastatin és simvastatin előállítására - Google Patents

Tisztítási eljárás csökkentett dimer szennyező tartalmú lovastatin és simvastatin előállítására

Info

Publication number
HUP0301214A2
HUP0301214A2 HU0301214A HUP0301214A HUP0301214A2 HU P0301214 A2 HUP0301214 A2 HU P0301214A2 HU 0301214 A HU0301214 A HU 0301214A HU P0301214 A HUP0301214 A HU P0301214A HU P0301214 A2 HUP0301214 A2 HU P0301214A2
Authority
HU
Hungary
Prior art keywords
simvastatin
reduced levels
dimeric impurities
lovastatin
purifying
Prior art date
Application number
HU0301214A
Other languages
English (en)
Inventor
Ilona Forgács
Vilmos Kéri
Original Assignee
Plus Chemicals S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Plus Chemicals S.A. filed Critical Plus Chemicals S.A.
Publication of HUP0301214A2 publication Critical patent/HUP0301214A2/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D309/28—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/30—Oxygen atoms, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pyrane Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)

Abstract

A találmány tárgya eljárás a dimerszennyeződés szintjének 0,08% alácsökkentésére statin vegyületekben 0,08%-nál több dimerszennyezésttartalmazó statin gyenge bázissal való kezelésével egy alkalmasoldószerelegyben. Ó
HU0301214A 2000-03-03 2001-02-27 Tisztítási eljárás csökkentett dimer szennyező tartalmú lovastatin és simvastatin előállítására HUP0301214A2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18686800P 2000-03-03 2000-03-03
PCT/US2001/006334 WO2001066538A1 (en) 2000-03-03 2001-02-27 A process for purifying lovastatin and simvastatin with reduced levels of dimeric impurities

Publications (1)

Publication Number Publication Date
HUP0301214A2 true HUP0301214A2 (hu) 2003-08-28

Family

ID=22686591

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0301214A HUP0301214A2 (hu) 2000-03-03 2001-02-27 Tisztítási eljárás csökkentett dimer szennyező tartalmú lovastatin és simvastatin előállítására

Country Status (18)

Country Link
US (1) US6521762B2 (hu)
EP (1) EP1265884A4 (hu)
JP (1) JP2003525935A (hu)
KR (1) KR20030069790A (hu)
CN (1) CN1443182A (hu)
AU (1) AU4183301A (hu)
CA (1) CA2402061A1 (hu)
CZ (1) CZ20023201A3 (hu)
DE (1) DE01913139T1 (hu)
HR (1) HRP20020730A2 (hu)
HU (1) HUP0301214A2 (hu)
IL (1) IL151583A0 (hu)
IS (1) IS6533A (hu)
PL (1) PL357533A1 (hu)
SK (1) SK13782002A3 (hu)
TR (1) TR200403001T3 (hu)
WO (1) WO2001066538A1 (hu)
ZA (1) ZA200207023B (hu)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100435078B1 (ko) * 2002-02-08 2004-06-09 종근당바이오 주식회사 심바스타틴의 정제방법
CA2548297C (en) * 2003-12-05 2011-06-14 Biocon Limited Process for the purification of macrolides
US7183285B2 (en) * 2004-04-29 2007-02-27 Pharmix Corp. Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase
US20050282883A1 (en) * 2004-04-29 2005-12-22 John Griffin Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase
US20050272770A1 (en) * 2004-04-29 2005-12-08 John Griffin Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase
US7199126B2 (en) * 2004-04-29 2007-04-03 Pharmix Corporation Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase
WO2006017263A1 (en) 2004-07-12 2006-02-16 Taro Pharmaceutical Industries Ltd. Topical gel formulation comprising organophosphate insecticide and its preparation thereof
US8158139B2 (en) * 2004-07-12 2012-04-17 Taro Pharmaceuticals North America, Inc. Topical gel formulation comprising organophosphate insecticide and preparation thereof
US20070015779A1 (en) * 2005-04-29 2007-01-18 John Griffin Compositions and treatments for inhibiting kinase and/or hmg-coa reductase
US7560445B2 (en) 2005-07-06 2009-07-14 Taro Pharmaceuticals North America, Inc. Process for preparing malathion for pharmaceutical use
US20090111997A1 (en) * 2005-11-23 2009-04-30 Aaron Cote Method of Generating Amorphous Solid for Water-Insoluble Pharmaceuticals
ES2372652T3 (es) 2007-05-23 2012-01-25 Amcol International Corporation Filosilicatos estratificados, que interactúan con el colesterol y métodos para reducir la hipercolesterolemia en un mamífero.

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5925599B2 (ja) 1979-02-20 1984-06-19 三共株式会社 新生理活性物質モナコリンｋおよびその製造法
US4294926A (en) 1979-06-15 1981-10-13 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
US4319039A (en) 1979-06-15 1982-03-09 Merck & Co., Inc. Preparation of ammonium salt of hypocholesteremic fermentation product
US4294846A (en) 1979-09-21 1981-10-13 Merck & Co., Inc. Hypocholesteremic fermentation products and products of preparation
US4342767A (en) 1980-01-23 1982-08-03 Merck & Co., Inc. Hypocholesteremic fermentation products
US4444784A (en) 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
US4420491A (en) 1980-05-28 1983-12-13 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
US4582915A (en) 1983-10-11 1986-04-15 Merck & Co., Inc. Process for C-methylation of 2-methylbutyrates
US4820850A (en) 1987-07-10 1989-04-11 Merck & Co., Inc. Process for α-C-alkylation of the 8-acyl group on mevinolin and analogs thereof
US4916239A (en) 1988-07-19 1990-04-10 Merck & Co., Inc. Process for the lactonization of mevinic acids and analogs thereof
US5202029A (en) * 1991-03-13 1993-04-13 Caron Kabushiki Kaisha Process for purification of hmg-coa reductase inhibitors
HU210867B (en) * 1992-11-04 1995-10-30 Biogal Gyogyszergyar Method for extraction and purification of mevinolin from culture medium
SI9300047A (en) 1993-01-29 1994-09-30 Krka Microbiological method for preparation of lovostatin and/or mevinoline acid
US5409820A (en) 1993-08-06 1995-04-25 Apotex, Inc. Process for the production of lovastatin using Coniothyrium fuckelii
AU7271696A (en) 1995-12-06 1997-06-27 Antibiotic Co Method of production of lovastatin
IN186880B (hu) 1997-10-28 2001-12-01 Ranbaxy Lab Ltd
IN186879B (hu) 1997-10-28 2001-12-01 Ranbaxy Lab Ltd
SI9800046A (sl) 1998-02-18 1999-08-31 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Postopek za pridobivanje inhibitorjev HMG-CoA reduktaze visoke čistosti
SI20072A (sl) 1998-09-18 2000-04-30 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Postopek za pridobivanje inhibitorjev HMG-CoA reduktaze
CA2388182A1 (en) 1999-10-27 2001-05-03 Merck & Co., Inc. Lactonization process

Also Published As

Publication number Publication date
CA2402061A1 (en) 2001-09-13
IL151583A0 (en) 2003-04-10
JP2003525935A (ja) 2003-09-02
KR20030069790A (ko) 2003-08-27
AU4183301A (en) 2001-09-17
DE01913139T1 (de) 2005-03-31
EP1265884A1 (en) 2002-12-18
CN1443182A (zh) 2003-09-17
TR200403001T3 (tr) 2005-02-21
EP1265884A4 (en) 2003-05-21
SK13782002A3 (sk) 2004-02-03
WO2001066538A1 (en) 2001-09-13
US6521762B2 (en) 2003-02-18
IS6533A (is) 2002-08-29
HRP20020730A2 (en) 2004-12-31
PL357533A1 (en) 2004-07-26
US20020002288A1 (en) 2002-01-03
ZA200207023B (en) 2003-09-02
CZ20023201A3 (cs) 2003-09-17

Similar Documents

Publication Publication Date Title
HUP0301214A2 (hu) Tisztítási eljárás csökkentett dimer szennyező tartalmú lovastatin és simvastatin előállítására
DE60138553D1 (de) Pharmazeutische zusammensetzung und verfahren zur behandlung von hypogonadismus
IS2113B (is) Ný sölt HMG-CoA redúktasatálma
ATE478665T1 (de) Verfahren zur herstellung einer polymorphen form von atorvastatin calcium
DE60037689D1 (de) Verwendung von Cubebol als Aromastoff
HK1027130A1 (en) Enzymatic processes for resolution of enantiome5icmixtures of compounds useful as intermediates in the preparation of taxanes.
DE60143850D1 (de) Verfahren zur behandlung von arzneimittelinduzierter peripherer neuropathie und verwandten krankheitsformen
PE20020850A1 (es) Utilizacion de compuestos de azetidinona sustituida para tratamiento de la sitosterolemia
HK1068136A1 (en) Muscarinic antagonists
DE69626864D1 (de) Abwasserbecken ZUR AEROBEN BEHANDLUNG VON ABWASSER beinhaltend Träger
UY26820A1 (es) Derivados de ciclopentil-glutaramida como inhibidores de endopeptidasa neutra
DE60233884D1 (de) 4(4-alkoxy-3-hydroxyphenyl)-2-pyrrolidon-derivate als pde-4-hemmer zur behandlung von neurologischen syndromen
AU2001271987A1 (en) Non-genotoxic metalloporphyrins as synthetic catalytic scavengers of reactive oxygen species
HUP0301124A2 (hu) Elszíneződésre nem hajlamos. minoxidil-tartalmú kompozíció és eljárás minoxidiltartalmú kompozíció elszíneződésének megakadályozására
NO20062656L (no) Fremgangsmate for fremstilling av statiner
ATE284396T1 (de) Verfahren zur bereitstellung von hochreinen hmg- coa reductase hemmer
ATE244710T1 (de) Verfahren zur herstellung von simvastatin und deren analogen
DE69333711D1 (de) Compactin zur behandlung von entzündungen
DE69608155D1 (de) Verwendung von Dioxabicyclo[3.3.0]octane zur Behandlung und Verhütung von zerebralen Apoplexie
AU6946891A (en) Di-and tetra-fluoro analogs of squalene as inhibitors of squalene epoxidase
DE59307409D1 (de) Verfahren zur Herstellung von (3R,5S)6-Hydroxy-3,5-0-isopropyliden-3,5-dihydroxy-hexansäure-tert.-butylester
DE60215368D1 (de) Pyranderivate als inhibitoren von ace und nep
ES2090840T3 (es) Procedimiento de purificacion de un hidrofluoroalcano.
ATE428425T1 (de) Spla2-inhibitoren zur behandlung von arteriosklerose
NO20030919D0 (no) Trombomodulinanaloger til anvendelse ved rekonvalesens etter ryggmargsskade